Dopaminergic drugs in development for Parkinson's disease

被引：0
|
作者：
Korczyn, AD [1 ]
机构：
[1] Tel Aviv Univ, Sch Med, Sieratzki Chair Neurol, Ramat Aviv, Israel
来源：
PARKINSON'S DISEASE | 2003年 / 91卷
关键词：
D O I：
暂无
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
引用
收藏
页码：267 / 271
页数：5
相关论文
共 50 条
  • [41] Continuous dopaminergic delivery in Parkinson’s disease
    Angelo Antonini
    Giulia Ursino
    Daniela Calandrella
    Laura Bernardi
    Mauro Plebani
    Journal of Neurology, 2010, 257 : 305 - 308
  • [42] Dysphagia and dopaminergic neurodegeneration in Parkinson's Disease
    Polychronis, S.
    Ribba, B.
    Nasios, G.
    Dardiotis, E.
    Pagano, G.
    MOVEMENT DISORDERS, 2023, 38 : S566 - S566
  • [43] Continuous dopaminergic delivery in Parkinson's disease
    Antonini, Angelo
    Ursino, Giulia
    Calandrella, Daniela
    Bernardi, Laura
    Plebani, Mauro
    JOURNAL OF NEUROLOGY, 2010, 257 : S305 - S308
  • [44] Dopaminergic Therapy in Parkinson's Disease: An Update
    Cristobal, Gurutz Linazasoro
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2008, 30 : 5 - 6
  • [45] Existing dopaminergic therapies for Parkinson's disease
    Dutta, Aloke K.
    Le, Weidong
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2006, 16 (12) : 1613 - 1625
  • [46] Parkinson's Disease, the Dopaminergic Neuron and Gammahydroxybutyrate
    Mamelak, Mortimer
    NEUROLOGY AND THERAPY, 2018, 7 (01) : 5 - 11
  • [47] Influence of mdr1 polymorphisms on sleepiness induced by dopaminergic drugs in Parkinson's disease
    Charbonnier-Beaupel, F.
    Allanic, F.
    Lacomblez, L.
    Hulot, J.
    Fernandez, C.
    Corvol, J.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2011, 25 : 20 - 21
  • [48] Abnormalities of short afferent inhibition of cutaneous stimulation in Parkinson's disease are reversed by dopaminergic drugs
    Tamburin, S
    Fiaschi, A
    Idone, D
    Manganotti, P
    Zanette, G
    MOVEMENT DISORDERS, 2005, 20 : S96 - S96
  • [49] Spectrophotometric determination of dopaminergic drugs used for Parkinson's disease, cabergoline and ropinirole, in pharmaceutical preparations
    Onal, Armagan
    Caglar, Sena
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2007, 55 (04) : 629 - 631
  • [50] Combined administration of dopaminergic and nondopaminergic drugs reverses neuroinflammation in a rat model of parkinson's disease
    Costa, G.
    Serra, M.
    Morelli, M.
    Pinna, A.
    JOURNAL OF NEUROCHEMISTRY, 2019, 150 : 83 - 83
12345